{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:33Z","timestamp":1791920253474,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.pcad.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T02:18:00Z","timestamp":1677982680000},"page":"12-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients"],"prefix":"10.1016","volume":"79","author":[{"given":"Satya Preetham","family":"Gunta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"O'Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan L.","family":"O'Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.pcad.2023.02.007_bb0005","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2023.02.007_bb0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","article-title":"Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat","volume":"4","author":"Mortensen","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2023.02.007_bb0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pcad.2023.02.007_bb0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1472-6947-9-18","article-title":"What is the point: will screening mammography save my life?","volume":"9","author":"Keen","year":"2009","journal-title":"BMC Med Inform Decis Mak"},{"issue":"8934","key":"10.1016\/j.pcad.2023.02.007_bb0025","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)","volume":"344","year":"1994","journal-title":"Lancet."},{"issue":"10155","key":"10.1016\/j.pcad.2023.02.007_bb0030","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.pcad.2023.02.007_bb0035","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0040","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1038\/s41598-020-66783-3","article-title":"Relationship between lipoprotein (a) and cognitive function - results from the Berlin aging study II","volume":"10","author":"Rohr","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.pcad.2023.02.007_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004249","article-title":"Prevalence and Management of Symptoms Associated with Statin Therapy in community practice: insights from the PALM (patient and provider assessment of lipid management) registry","volume":"11","author":"Navar","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"10.1016\/j.pcad.2023.02.007_bb0055","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/2047487315586096","article-title":"Statin-associated muscle injury","volume":"22","author":"Ballard","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2023.02.007_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043714","article-title":"Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients","volume":"11","author":"Davis","year":"2021","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.pcad.2023.02.007_bb0065","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ncl.2014.04.009","article-title":"Toxic myopathies","volume":"32","author":"Pasnoor","year":"2014","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.02.007_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.006","article-title":"Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis","volume":"299","author":"Kennedy","year":"2020","journal-title":"Atherosclerosis."},{"issue":"12","key":"10.1016\/j.pcad.2023.02.007_bb0080","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.02.007_bb0085","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ."},{"issue":"8","key":"10.1016\/j.pcad.2023.02.007_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3189","article-title":"Statin users have an elevated risk of dysglycemia and new-onset-diabetes","volume":"35","author":"Zigmont","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0095","first-page":"25","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein - an analysis","volume":"31","author":"Levinson","year":"2008","journal-title":"J Clin Ligand Assay"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12933-022-01524-6","article-title":"Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases","volume":"21","author":"Seo","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.pcad.2023.02.007_bb0105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamainternmed.2014.1927","article-title":"Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins?","volume":"174","author":"Sugiyama","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pcad.2023.02.007_bb0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajo.2020.05.007","article-title":"Association of dry eye disease with dyslipidemia and statin use","volume":"218","author":"Aldaas","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.pcad.2023.02.007_bb0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ceo.13388","article-title":"Association of dyslipidaemia and oral statin use, and dry eye disease symptoms in the Blue Mountains eye study","volume":"47","author":"Ooi","year":"2019","journal-title":"Clin Experiment Ophthalmol"},{"issue":"8","key":"10.1016\/j.pcad.2023.02.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237617","article-title":"Comparison between high and low potency statins in the incidence of open-angle glaucoma: a retrospective cohort study in Japanese working-age population","volume":"15","author":"Ooba","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.pcad.2023.02.007_bb0125","article-title":"Association between statin use and the risks of glaucoma in Australia: a 10-year cohort study","volume":"318789","author":"Yuan","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0130","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1038\/s41598-018-24248-8","article-title":"Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis","volume":"8","author":"Chu","year":"2018","journal-title":"Sci Rep"},{"issue":"30","key":"10.1016\/j.pcad.2023.02.007_bb0135","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011304","article-title":"Statins use and risk of dementia: a dose-response meta analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"25","key":"10.1016\/j.pcad.2023.02.007_bb0140","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.jacc.2021.04.075","article-title":"Effect of statin therapy on cognitive decline and incident dementia in older adults","volume":"77","author":"Zhou","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.02.007_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/292598","article-title":"Cholesterol: its regulation and role in central nervous system disorders","volume":"2012","author":"Orth","year":"2012","journal-title":"Cholesterol."},{"key":"10.1016\/j.pcad.2023.02.007_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.690372","article-title":"Cholesterol and Alzheimer\u2019s disease; from risk genes to pathological effects","volume":"13","author":"Feringa","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"10.1016\/j.pcad.2023.02.007_bb0155","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1592\/phco.26.8.1190","article-title":"Short-term memory loss associated with rosuvastatin","volume":"26","author":"Galatti","year":"2006","journal-title":"Pharmacotherapy."},{"issue":"3","key":"10.1016\/j.pcad.2023.02.007_bb0160","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.pcad.2023.02.007_bb0165","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","article-title":"Statin use and risk of dementia or Alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies","volume":"29","author":"Olmastroni","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10.1016\/j.pcad.2023.02.007_bb0170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pcad.2023.02.007_bb0175","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.pcad.2023.02.007_bb0180","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation."},{"issue":"22","key":"10.1016\/j.pcad.2023.02.007_bb0185","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pcad.2023.02.007_bb0190","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.pcad.2023.02.007_bb0195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2023.02.007_bb0200","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.pcad.2023.02.007_bb0205","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2023.02.007_bb0210","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.clinthera.2021.02.002","article-title":"Effectiveness, safety, and adherence to treatment of proprotein convertase Subtilisin\/Kexin type 9 inhibitors in real practice","volume":"43","author":"Gayoso-Rey","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.pcad.2023.02.007_bb0215","doi-asserted-by":"crossref","first-page":"8129513","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-a narrative review","volume":"2022","author":"Mercep","year":"2022","journal-title":"Cardiovasc Ther"},{"issue":"6","key":"10.1016\/j.pcad.2023.02.007_bb0220","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/0129784-200808060-00005","article-title":"Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model","volume":"8","author":"Ara","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"25","key":"10.1016\/j.pcad.2023.02.007_bb0225","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pcad.2023.02.007_bb0230","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"issue":"10349","key":"10.1016\/j.pcad.2023.02.007_bb0235","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.pcad.2023.02.007_bb0240","series-title":"Ezetimibe","author":"Sizar","year":"2022"},{"issue":"10263","key":"10.1016\/j.pcad.2023.02.007_bb0245","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.pcad.2023.02.007_bb0250","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2023.02.007_bb0255","first-page":"92","article-title":"Trends in utilization and cost of low-density lipoprotein cholesterol-lowering therapies among Medicare beneficiaries: an analysis from the medicare part D database","volume":"6","author":"Sumarsono","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2023.02.007_bb0260","first-page":"84","article-title":"Bempedoic acid: a novel oral LDL-cholesterol lowering agent","volume":"14","author":"Jialal","year":"2022","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"6","key":"10.1016\/j.pcad.2023.02.007_bb0265","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.pcad.2023.02.007_bb0270","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","author":"Nissen","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.pcad.2023.02.007_bb0275","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.pcad.2023.02.007_bb0280","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"39","key":"10.1016\/j.pcad.2023.02.007_bb0285","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.02.007_bb0290","article-title":"PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis","volume":"377","author":"Khan","year":"2022","journal-title":"BMJ."},{"issue":"23","key":"10.1016\/j.pcad.2023.02.007_bb0295","first-page":"2776","article-title":"Goal achievement after utilizing an anti-PCSK9 antibody in statin intolerant subjects (GAUSS): interim results from a randomized, double-blind, placebo-controlled study","volume":"126","author":"Sullivan","year":"2012","journal-title":"Circulation"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:21:24Z","timestamp":1758500484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062023000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":59,"alternative-id":["S0033062023000130"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2023.02.007","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}